Preliminary Experiment on the Effect of 18% Substitute Salt on Home Blood Pressure Variability in Hypertensives

Jing Li,1,2 Lisha Mu,2 Huakun Rao,2 Yangfeng Wu,3 Hao Wang,4 Hongbing Tao,1 and Lihong Mu2

1 Tongji Medical College of Huazhong University of Science and Technology School, Wuhan, China
2 School of Public Health and Management, Research Center for Medicine and Social Development, Innovation Center for Social Risk Governance in Health, Chongqing Medical University, Chongqing, China
3 Peking University School of Public Health and Clinical Research Institute, Beijing, China
4 Chongqing Nan’an District People’s Hospital, Chongqing, China

Correspondence should be addressed to Hongbing Tao; hhbtao@hust.edu.cn and Lihong Mu; 1097123703@qq.com

Received 2 April 2021; Revised 13 August 2021; Accepted 18 August 2021; Published 3 September 2021

At present, the effect of substitute salt in reducing sodium intake and blood pressure is relatively clear. The present study is a phase I clinical trial involving 43 hypertensives in which the effect of 18% sodium substitute salt on the home blood pressure variability (BPV) was observed for 8 weeks with weekly follow-up. Finally, 4 patients were lost, and 39 patients completed the intervention and were included in the analysis. Daily home blood pressure and weekly adverse events were collected. The systolic blood pressure (SBP) in the morning (−10.0 mmHg, 95% CI: −16.5 to −3.5, P = 0.003), SBP at night (−10.2 mmHg, 95% CI: −16.1 to −4.3, P = 0.001), and diastolic blood pressure (DBP) at night (−4.0 mmHg, 95% CI: −7.1 to −0.8, P = 0.014) decreased significantly. Also, there was no statistically significant change in morning (F = 1.137, P = 0.352) and night diastolic (F = 0.344, P = 0.481) BPV and morning systolic BPV (F = 0.663, P = 0.930) over time during the intervention period, except for that night systolic BPV had a downward trend (F = 2.778, P = 0.016) and had decreased 2.04 mmHg (95% CI: 0.84 to 3.23, P = 0.001) after intervention. The use of 18% of the substitute salt did not increase BPV during the intervention and even may decrease it, which indicates its control effects on blood pressure. This study is the first one to observe the effect of 18% sodium substitute salt on the home blood pressure variability, providing a basis for further experiments.

1. Introduction

It is well known that excessive salt intake is closely related to an increase in blood pressure and the risk of cardiovascular-related events [1]. The World Health Organization recommends that the daily salt intake per person should be less than 5 g per day, while current salt intake is about 12 g or more in many countries, including China [2]. Therefore, it is imperative to find an effective salt restriction measure. Studies have shown that substitute salt is a more cost-effective measure to restrict salt intake [3, 4]. Research showed that substitute salt can lower the blood pressure (−7.52/−4.25 mmHg) compared to common salt [5–9]. Spontaneous variation in blood pressure is referred to as BPV due to the effects of day and night changes, weather changes, and other factors [10, 11]. A large number of studies [12–14] have confirmed that blood pressure variability is closely related to the risk of future cardiovascular events in patients with hypertension and is an independent predictor of blood pressure mean, which has an important prognostic value for patients with hypertension [15]. However, there has been little research on the effect of substitute salt on BPV. This study aimed to investigate whether the intake of alternative salts would alter BPV in patients with hypertension.
2. Methods

2.1. Participants. This study was completed in the Public Health Department of the People’s Hospital of Nan’an District, Chongqing, China. A total of 43 patients diagnosed with primary hypertension were included from May to July 2018. Inclusion criteria: (1) age in the range of ≥50 and ≤75 years; (2) not having plans to move out of the community in the next three months; (3) not cooking at home less than 3 times or one day during the study; and (4) written informed consent provided before enrollment in the trial. Exclusion criteria: (1) history of acute myocardial infarction or stroke in the past 3 months and history of malignancy or expected lifetime less than 1 year; (2) hypercortisolism or aldosteroneism; (3) acute disease, such as upper respiratory infection, fever, and diarrhea; (4) disease or disabilities that could exert potential influence on their adherence to the intervention, including deafness and dementia, as well as severe depression and other mental disorders; (5) salt substitute use in the family; (6) family members not willing to use the salt substitute; (7) chronic renal failure at stage 4 or above or with renal replacement therapy; (8) abnormal liver function, with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level greater than 2 times the upper limit of normal, or total bilirubin level greater than the upper limit of normal; and (9) abnormal blood potassium level, <3.5 mmol/L or >5.5 mmol/L, or current use of potassium-preserving diuretics. The study has been approved by the Institutional Review Board of Peking University (IRB00001052–17110). The trial was registered at http://www.clinicaltrials.gov (NCT03226327).

2.2. Study Design and Intervention. This study is a phase I clinical trial of single arm. After the subjects and their family signed the informed consent, subjects completed baseline questionnaires and medical examination (including general physical examination, blood pressure, and 24-hour urine test). 18% substitute salt instead of traditional salt was used for 8 weeks, and patients were measured home blood pressure every day, while follow-up staff visited the patients once a week to collect information of antihypertensive drug use and safety.

2.3. Materials and Instruments. In this study, the 18% sodium substitute salt of “Man Li Kang” was developed by Chongqing Institute of Biotechnology Co., Ltd.: name: solid compound condiment, standard of execution:Q/SWS0025S, food production license number: SC10650012000709, and food circulation permit: SP5009051610016538, and the main ingredients include potassium chloride (35%), sodium chloride(18%), and calcium chloride(10%). The blood pressure measuring instrument adopts a pulse-wave electronic sphygmomanometer (RBP-9801).

2.4. Blood Pressure Measurement. Before the start of the study, follow-up staff was trained in relevant knowledge of blood pressure measurement. Then, each subject was trained in blood pressure measurement by the follow-up staff, and a home blood pressure measurement handbook was distributed to all subjects. Patients were required to complete 3 blood pressure measurements at time in the morning and evening (from 6 to 9 o’clock am/pm) every day. Besides, during the weekly follow-up, the follow-up staff would confirm with the subjects whether the blood pressure measurement method is correct or not. Also, the blood pressure measurement results were automatically uploaded to the terminal management system in real time through the device. The researchers collected the blood pressure data for 8 weeks for sorting and analysis.

2.5. Substitute Salt Weighing and 24-Hour Urine Test. Follow-up staff used a uniform electronic scale to weigh the weekly salt used by each patient and calculate the weekly salt usage of the patient.

The 24-hour urine of patients was collected at baseline and after the intervention, sent to a local grade-A tertiary hospital for testing. The items include 24-hour urinary sodium, potassium, calcium, magnesium, urinary creatinine (Cr), and urinary microalbumin (U-ALB).

2.6. Statistical Analysis. Three blood pressure measurements were required per time, and the last 2 averages were included in the analysis. BPV is represented by standard deviation (SD) of blood pressure per week. The baseline blood pressure was taken as an average measured three times, respectively, in the morning and evening on the first day of intervention.

Statistical analysis was carried out using SPSS 22.0 (IBM, Armonk, NY, USA). A total of 1953 pieces of complete blood pressure measurement data were collected in the morning, with a missing rate of 9.45% and 1871 in the evening, with a missing rate of 14.33%. The missing data of home blood pressure were filled by multiple imputations [16]. Quantitative normal distribution data are described by mean and standard deviation, and qualitative data are described by frequency. Urine sodium and potassium before and after intervention were compared using the paired T, and the linear mixed models were used to analyze the change of blood pressure and its variability. P values less than 0.05 were considered statistically significant.

3. Results

3.1. Baseline. In this study, we enrolled 43 patients, with 4 lost because of the intolerability of the taste of the substitute salt. 39 patients were finally analyzed by per protocol (PP), including 20 males and 19 females, aged 67.1 ± 7.9 years, with a body mass index (BMI) of 26.6 ± 3.6. Among them, 14 subjects reduced the doses of antihypertensive drugs and 25 subjects had the doses unchanged. Blood pressure at baseline is shown in Table 1.

3.2. Use of 18% Substitute Salt and the 24-Hour Urine Test. After 8 weeks of intervention, the urine potassium increased by 8.79 mmol/24 h on average (P = 0.021), urinary sodium/
potassium decreased significantly compared with baseline \( (P = 0.001) \), and urine sodium decreased by 13.82 mmol/24 h on average, but there was no statistically significant difference \( (P = 0.220) \). U-A LB/Cr increased compared with baseline \( (P = 0.002) \), but urine calcium and magnesium had no significant changes compared with baseline \( (P > 0.05) \) (Table 2). The per capita salt of the subjects weighed by the follow-up staff each week was around 3–5 g/d (Figure 1).

### 3.3. Blood Pressure and Its Variability

The analysis of the mixed linear model showed that the SBP in the morning \( (−10.0 \text{ mmHg}, 95\% \text{ CI: } −16.5 \text{ to } −3.5, P = 0.003) \), SBP at night \( (−10.2 \text{ mmHg, 95\% CI: } −16.1 \text{ to } −4.3, P = 0.001) \), and DBP at night \( (−4.0 \text{ mmHg, 95\% CI: } −7.1 \text{ to } −0.8, P = 0.014) \) all decreased significantly compared with the baseline. Also, the SBP in the morning \( (−7.6 \text{ mmHg, 95\% CI: } −14.1, −1.1, P = 0.023) \) decreased significantly at 3 weeks, and the SBP at night \( (−7.8 \text{ mmHg, 95\% CI: } −13.7, −2.0, P = 0.010) \) dropped at 2 weeks (Table 3). There was no statistically significant trend change in morning \( (F = 1.137, P = 0.352) \) and night diastolic \( (F = 0.344, P = 0.481) \) BPV and morning systolic BPV \( (F = 0.663, P = 0.930) \) over time during the intervention period, except for that night systolic BPV had a downward trend \( (F = 2.778, P = 0.016) \) and had decreased by 2.04 mmHg \( (95\% \text{ CI: } 0.84 \text{ to } 3.23, P = 0.001) \) after intervention. Furthermore, the night diastolic BPV \( (−0.22 \text{ mmHg, 95\% CI: } −0.97 \text{ to } 0.52, P = 0.553) \) and morning systolic BPV \( (−0.66 \text{ mmHg, 95\% CI: } −1.98 \text{ to } 0.65, P = 0.319) \) also decreased, but the difference was not statistically significant (Figure 2). The data of morning and evening systolic BPV are seen in Table 4.

### 3.4. Safety

No serious adverse events occurred during the intervention. Other adverse events included the following: one patient had constipation at the first week, two patients developed fatigue, two patients developed dizziness and headache, and one patient had itching in the neck, back, and abdomen at the 3rd week.

### Table 1: Demographic, clinical characteristics, and blood pressure at baseline.

| Variables                        | All populations \((n = 39)\) |
|----------------------------------|------------------------------|
| Age, years \((\text{mean } \pm \text{SD})\) | 67.1 \(\pm\) 7.9 |
| Male \((n, \%)\)                    | 20 \((51.3)\) |
| BMI, kg/m² \((\text{mean } \pm \text{SD})\) | 26.6 \(\pm\) 3.6 |
| Age of hypertension, years \((\text{mean } \pm \text{SD})\) | 11.0 \(\pm\) 6.3 |
| Complicated other diseases* \((n, \%)\) | 19 \((48.7)\) |
| Smoke \((n, \%)\)                  | 4 \((10.3)\) |
| Drink \((n, \%)\)                  | 6 \((18.2)\) |
| Exercises \((n, \%)\)              | 4 \((10.3)\) |
| Follow-up SBP, mmHg \((\text{mean } \pm \text{SD})\) | 135.1 \(\pm\) 16.8 |
| Follow-up DBP, mmHg \((\text{mean } \pm \text{SD})\) | 72.6 \(\pm\) 8.2 |
| Morning SBP, mmHg \((\text{mean } \pm \text{SD})\) | 136.4 \(\pm\) 18.7 |
| Morning DBP, mmHg \((\text{mean } \pm \text{SD})\) | 76.3 \(\pm\) 8.7 |
| Evening SBP, mmHg \((\text{mean } \pm \text{SD})\) | 134.7 \(\pm\) 18.1 |
| Evening DBP, mmHg \((\text{mean } \pm \text{SD})\) | 74.3 \(\pm\) 9.7 |

*Complicated other diseases include stroke, coronary heart disease, and diabetes mellitus.

### 4. Discussion

The Guidelines for Rational Use of Medicine in China suggest that it should be necessary to follow the principle of long-term efficacy and stability in regard to controlling blood pressure [17], which can prevent the occurrence of complications of cardiovascular and cerebrovascular diseases more effectively [18, 19]. Therefore, as a good measure to control the blood pressure in hypertensive patients, not only should it have the effect of lowering blood pressure but also, more importantly, maintain blood pressure stability.

The sodium content of traditional substitute salt is high, usually around 70% [7, 8], and some may be as low as 50% or even 25% [9, 20]. Previous salt-restricted studies have also shown that, in the case of relatively high sodium intake, the lower the sodium intake, the lower the blood pressure [21–23]. As an objective standard for measuring sodium and potassium intake, the 24-hour urine test has been widely used in scientific research. An international multicenter study showed that 24-h urine sodium/potassium was positively correlated with blood pressure, while 24-h urine potassium was negatively correlated with blood pressure [24]. A latest systematic review shows that the potassium intake of the Chinese population has been at a low level for the past 40 years, and the intake in all age groups is only half the recommended minimum or even lower [25]. The results of this study showed that, after 8 weeks of 18% substitute salt intervention, 24-hour urine potassium was significantly increased, while 24-hour sodium/potassium decreased, which indicates that this low-sodium salt has a more significant effect in increasing potassium intake. However, the effect of 24-hour urine sodium reduction is not obvious, which may be related to local eating habits of Chongqing people (preference for pickles, bean paste, and other high-salt foods).

Before intervention, we collected the clinical blood pressure of the patient at baseline, and the family self-measured blood pressure during 8 weeks of intervention. Compared to the baseline, we observed a decrease in blood pressure in the first week of the intervention and then a greater decrease in the second and three weeks. We have conducted a more detailed analysis of visit and home blood pressure in a separate article [26]. The SBP (SBP am: \(-10.0 \text{ mmHg and SBP pm: } −10.2 \text{ mmHg} \) of patients seems to have dropped more than in previous studies \((−7.52 \text{ mmHg}) \) [5]. Also, there was a significant drop in blood pressure during the second week of the intervention, which appeared earlier than most previous studies [27–29]. In a prospective cohort study using 65% substitute salt, the blood pressure of hypertensive patients was not significantly reduced even after 18 months of intervention [29]. Based on these, we were concerned that the substitute salt (18% sodium content only) used in this study would lead to an increase in blood pressure variability due to lowering the blood pressure in a short time. However, in this study, we found that the patient’s BPV did not increase significantly, and the variability of night systolic blood pressure even decreased during the intervention.

Previous studies have shown that the results of BPV are closely related to the number of blood pressure
Table 2: Changes of the 24-hour urine test before and after intervention.

| Intervention | Sodium (mmol/24h) | Potassium (mmol/24h) | Sodium/potassium | Calcium (mmol/24h) | Magnesium (mmol/24h) | U-ALB/Cr (mg/g) |
|--------------|-------------------|----------------------|------------------|-------------------|----------------------|----------------|
| Before       | 151.86 ± 55.93    | 52.22 ± 19.30        | 3.05 (1.95–4.36) | 5.41 ± 2.40       | 4.35 ± 1.68          | 3.2 (1.9–6.6)   |
| After        | 138.05 ± 57.12    | 61.01 ± 17.26        | 2.39 (1.44–3.28) | 5.81 ± 3.23       | 4.77 ± 1.64          | 4.6 (2.8–4.7)   |
| Change       | 13.82 ± 69.23     | −8.79 ± 22.76        | 0.62 (−0.19–1.58) | −0.40 ± 2.62      | −0.42 ± 1.43         | −1.2 (−5.4–0.0) |

Table 3: Changes in blood pressure from baseline during intervention, mean (95% CI)*.

| Week | SBP am Statistics | P* | SBP pm Statistics | P* | DBP am Statistics | P* | DBP pm Statistics | P* |
|------|-------------------|----|-------------------|----|-------------------|----|-------------------|----|
| Baseline | 136.0 (130.2, 140.7) | – | 133.8 (128.5, 139.0) | – | 76.6 (74.2, 78.9) | – | 74.4 (71.9, 77.0) | – |
| 1 | −3.1 (−10.0, 3.7) | 0.365 | −4.8 (−10.9, 1.4) | 0.124 | −0.6 (−3.9, 2.6) | 0.705 | −1.9 (−5.1, 1.4) | 0.253 |
| 2 | −6.2 (−12.7, 0.3) | 0.060 | −7.8 (−13.7, −2.0) | 0.010 | −1.7 (−4.9, 1.5) | 0.284 | −3.0 (−6.1, 0.2) | 0.063 |
| 3 | −7.6 (−14.1, −1.1) | 0.023 | −8.6 (−14.8, −2.4) | 0.007 | −2.0 (−5.3, 1.3) | 0.232 | −2.7 (−5.8, 0.4) | 0.082 |
| 4 | −8.9 (−15.4, −2.4) | 0.008 | −9.3 (−15.2, −3.4) | 0.002 | −2.2 (−5.6, 1.1) | 0.189 | −3.3 (−6.4, −0.3) | 0.033 |
| 5 | −9.9 (−16.2, −3.6) | 0.003 | −11.0 (−16.8, −5.1) | <0.001 | −3.6 (−6.6, −0.6) | 0.018 | −3.9 (−7.0, −0.8) | 0.014 |
| 6 | −8.7 (−15.1, −2.3) | 0.009 | −10.1 (−15.8, −4.3) | 0.001 | −2.8 (−6.0, 0.3) | 0.078 | −3.4 (−6.5, −0.3) | 0.031 |
| 7 | −11.0 (−17.2, −4.7) | 0.001 | −11.9 (−17.8, −6.1) | <0.001 | −3.3 (−6.4, −0.1) | 0.041 | −4.2 (−7.3, −1.1) | 0.009 |
| 8 | −10.0 (−16.5, −3.5) | 0.003 | −10.2 (−16.1, −4.3) | 0.001 | −2.8 (−6.1, 0.5) | 0.097 | −4.0 (−7.1, −0.8) | 0.014 |

* Adjusted for sex, age, body mass index, and reduction of antihypertensive drugs in the linear mixed model.

measurements [30, 31] and 6 blood pressure measurements are the minimum number of measurements that can better predict the occurrence of cardiovascular events [13]. In this study, blood pressure were measured 7 times a week to observe the BPV during the use of substitute salt, which can achieve a better response to BPV as well as better reflect the change cycle of blood pressure.

A study by Ozkayar et al. [32] showed that ambulatory blood pressure variability was positively correlated with dietary salt intake. In this study, BPV was the largest in the first week of intervention but decreased gradually during the intervention. The possible reasons for this decrease include reduction of salt use and ultra-low sodium chloride content, as well as effects of comprehensive factors such as regular medication, blood pressure management, and salt-sensitive population. However, as intervention continued, the body’s own function was adjusted. When the blood pressure fell to the extent for the body to adapt, we observed that the variability of blood pressure gradually decreased.

There are still some limitations in this study. Firstly, the study was based on a phase I clinical trial that resulted in a limited sample size, and there are possibly sampling errors that make the results unstable. Furthermore, we used the BPV in the first week of intervention as the reference to observe the changes in BPV of patients during the intervention. If BPV decreased and stabilized in the first week of intervention due to the 18% substitute salt with gold sodium potassium ratio of 1:2, the effect of intervention may be underestimated. On the other hand, if BPV was significantly increased in the first week due to the influence of comprehensive factors compared with before the intervention, but as the intervention continued, the BPV gradually
decreased after the body adapted to the intervention, the effect of this salt in reducing BPV would be overestimated.

5. Conclusions

Although 18% substitute salt has lower sodium content, its application in hypertensive patients did not cause an increase in blood pressure variability and even reduced the evening systolic blood pressure variability of the patients, which indicates that the 18% substitute salt has a good effect of controlling blood pressure. However, further long-term randomized controlled trials are still needed to verify this finding.

Data Availability

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Disclosure

The funder had no role in the design, implementation, data collection, analysis, and article writing process of the study.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This study was funded by the “13th Five-Year Plan” of the National Science and Technology Support Program, “Study on Key Technologies and Application Strategies of Nutrition and Behavior Intervention in Cardiovascular and Cerebrovascular Diseases,” (2016fc13000200), Chongqing Science and Technology Bureau (Project No. cstc2019jxcsxmX0267), Chongqing Science and Technology Commission (Project No. cstc2017jsyj-zdcxBX0016), and Health Source (Chongqing) Cardiovascular Health Technology Co., Ltd.

References

[1] P. Rust and C. Ekmeckioglu, “Impact of salt intake on the pathogenesis and treatment of hypertension,” Advances in Experimental Medicine and Biology, vol. 956, pp. 61–84, 2017.
[2] M. Wang, A. E. Moran, J. Liu et al., “A meta-analysis of effect of dietary salt restriction on blood pressure in Chinese adults,” Global heart, vol. 10, no. 4, pp. 291–299, 2015.
[3] E. Schorling, D. Niebuhr, and A. Kroke, “Cost-effectiveness of salt reduction to prevent hypertension and CVD: a systematic review,” Public Health Nutrition, vol. 20, no. 11, pp. 1993–2003, 2017.

[4] N. Nghiem, T. Blakely, L. J. Cobiac, C. L. Cleghorn, and N. Wilson, “The health gains and cost savings of dietary salt reduction interventions, with equity and age distributional aspects,” BMC Public Health, vol. 16, no. 1, pp. 423–513, 2016.

[5] A. V. Hernandez, E. E. Emonds, B. A. Chen et al., “Systematic review and meta-analysis of the effects of low sodium salt substitutes on cardiovascular outcomes,” Journal of the American College of Cardiology, vol. 71, no. 11, p. A1749, 2018.

[6] N. Li, J. Prescott, Y. Wu et al., “The effects of a reduced-sodium, high-potassium salt substitute on food taste and acceptability in rural northern China,” British Journal of Nutrition, vol. 101, no. 7, pp. 1088–1093, 2009.

[7] B. Zhou, J. Webster, L.-Y. Fu et al., “Intake of low sodium salt substitute for 3 years attenuates the increase in blood pressure in a rural population of North China—a randomized controlled trial,” International Journal of Cardiology, vol. 215, pp. 377–382, 2016.

[8] X. Zhao, X. Yin, X. Li et al., “Using a low-sodium, high-potassium salt substitute to reduce blood pressure among Tibetans with high blood pressure: a patient-blinded randomized controlled trial,” PLoS One, vol. 9, no. 10, Article ID e110131, 2014.

[9] E. S. Sarkkinen, M. J. Kastarinen, T. H. Niskanen et al., “Feasibility and antihypertensive effect of replacing regular salt with mineral salt –rich in magnesium and potassium– in subjects with mildly elevated blood pressure,” Nutrition Journal, vol. 10, no. 1, pp. 88–89, 2011.

[10] G. Mancia, “Short- and long-term blood pressure variability,” Hypertension, vol. 60, no. 2, pp. 512–517, 2012.

[11] G. Parati, J. E. Ochoa, C. Lombardi, P. Salvi, and G. Bilo, “Assessment and interpretation of blood pressure variability in a clinical setting,” Blood Pressure, vol. 22, no. 6, pp. 345–354, 2013.

[12] A. J. Webb, U. Fischer, Z. Mehta, and P. M. Rothwell, “Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis,” The Lancet, vol. 375, no. 9718, pp. 906–915, 2010.

[13] H. M. Lim, Y. C. Chia, S. M. Ching, and K. Chinna, “Number of blood pressure measurements needed to estimate long-term visit-to-visit systolic blood pressure variability for predicting cardiovascular risk: a 10-year retrospective cohort study in a primary care clinic in Malaysia,” BMJ Open, vol. 9, no. 4, Article ID e025322, 2019.

[14] T. I. Chang, G. H. Tabada, J. Yang, T. C. Tan, and A. S. Go, “Visit-to-visit variability of blood pressure and death, end-stage renal disease, and cardiovascular events in patients with chronic kidney disease,” Journal of Hypertension, vol. 34, no. 2, pp. 244–252, 2016.

[15] J.-m. Yu, Q.-y. Kong, P. Schoenhagen et al., “The prognostic value of long-term visit-to-visit blood pressure variability on stroke in real-world practice: a dynamic cohort study in a large representative sample of Chinese hypertensive population,” International Journal of Cardiology, vol. 177, no. 3, pp. 995–1000, 2014.

[16] A. Mackinnon, “The use and reporting of multiple imputation in medical research—a review,” Journal of Internal Medicine, vol. 268, no. 6, pp. 586–593, 2010.

[17] National Health and Family Planning Commission Committee on Rational Use of Medicine, “Chinese society of hypertension professional committee,” Guidelines for rational use of hypertension,” Chinese Journal of Frontier Medicine (Electronic Edition), vol. 97, pp. 28–126, 2nd edition, 2017.

[18] K. Kario, I. Saito, T. Kushiro et al., “Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy,” Hypertension, vol. 64, no. 5, pp. 989–996, 2014.

[19] M. J. Brown, C. R. Palmer, A. Castaigne et al., “Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: intervention as a Goal in Hypertension Treatment (INSIGHT),” The Lancet, vol. 356, no. 9227, pp. 366–372, 2000.

[20] A. Bernabeoortiz, F. Dieczenacco, R. H. Gilman et al., “Launching a salt substitute to reduce blood pressure at the population level: a cluster randomized stepped wedge trial in Peru,” Trials, vol. 15, no. 1, 2014.

[21] L. Van Horn, “Dietary sodium and blood pressure: how low should we go?” Progress in Cardiovascular Diseases, vol. 58, no. 1, pp. 61–68, 2015.

[22] F. J. He, M. Marciniak, E. Visagie et al., “Effect of modest salt reduction on blood pressure, urinary albumin, and pulse wave velocity in white, black, and Asian mild hypertensives,” Hypertension, vol. 54, no. 3, pp. 482–488, 2009.

[23] F. J. He, J. Li, and G. A. Macgregor, “Effect of longer term modest salt reduction on blood pressure: cochrane systematic review and meta-analysis of randomised trials,” BMJ, vol. 346, p. f1325, 2013.

[24] Intersalt, “Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group,” BMJ; vol. 297, no. 6644, pp. 319–328, 1988.

[25] H. Tan, F. J. He, C. Wang et al., “Twenty-four-hour urinary sodium and potassium excretion in China: a systematic review and meta-analysis [I],” Journal of the American Heart Association, vol. 8, no. 14, Article ID e012923, 2019.

[26] T. Liu, H. Rao, M. Wang et al., “Comparative analysis of visit and home blood pressure in a pilot trial on the effect of 18% sodium substitute salt on blood pressure,” Scientific Reports, vol. 11, no. 1, p. 907, 2021.

[27] F. M. Sacks, L. P. Svetkey, W. M. Vollmer et al., “Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet,” New England Journal of Medicine, vol. 344, no. 1, pp. 3–10, 2001.

[28] S. P. Juraschek, M. Woodward, F. M. Sacks, V. J. Carey, E. R. Miller, and L. J. Appel, “Time course of change in blood pressure from sodium reduction and the DASH diet,” Hypertension, vol. 70, no. 5, pp. 923–929, 2017.

[29] J. Hu, L. Zhao, B. Thompson et al., “Effects of salt substitute on home blood pressure differs according to age and degree of blood pressure in hypertensive patients and their families,” Clinical and Experimental Hypertension, vol. 40, no. 7, pp. 664–672, 2018.

[30] E. B. Levitan, N. Kaciroti, S. Oparil, S. Julius, and P. Muntner, “Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure,” Journal of Clinical Hypertension, vol. 14, no. 11, pp. 744–750, 2012.

[31] P. Muntner and E. B. Levitan, “Visit-to-visit variability of blood pressure,” Blood Pressure Monitoring, vol. 18, no. 4, pp. 232–238, 2013.

[32] N. Ozkayar, F. Dede, I. Ates, F. Akyel, T. Yildirim, and B. Altun, “The relationship between dietary salt intake and ambulatory blood pressure variability in non-diabetic hypertensive patients,” Nefrologia, vol. 36, no. 6, pp. 694–700, 2016.